Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player
Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene…
Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene…
Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T…
Try as we might, we can’t cover all the biotech news out there! Here’s a roundup…
UPDATE: The FDA has lifted both clinical holds provided that Cellectis decreases the dose of…
Gilead's CAR-T cell therapy Yescarta has been approved by the FDA, making it the first…
Everything you need to know about CAR-T, a revolutionary cell therapy for cancer. You might…
Celyad has announced early results from a clinical trial, where a patient has been cleared of…
Autolus, based in London, has raised €68M in Series C to continue developing its T cell…
As we anticipate the first-ever CAR-T therapy market approval we look at the important aspect…
Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently…
The FDA has approved Novartis' CAR-T therapy Kymriah, opening the way for a new generation…
European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’…